Screener
ARS Pharmaceuticals, Inc. SPRY Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Contract liability, current | 757 | 609 |
| Other current liabilities | 592 | 588 |
| Total current liabilities | 49,612 | 39,145 |
| Term loans, net (including related party amounts of $4,826 and $4,819, respectively) | 96,522 | 96,374 |
| Financing liability | 74,673 | 72,140 |
| Contract liability, net of current portion | 978 | 1,130 |
| Other accrued liabilities | 4,478 | 4,605 |
| Total liabilities | 226,263 | 213,394 |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s long-term debt?
- ARS Pharmaceuticals, Inc. (SPRY) reported long-term debt of $96.52M in Q1 2026.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s long-term debt?
- Over 3 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s long-term debt has grown at a 169.4% compound annual growth rate (CAGR), from $4.93M to $96.37M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about ARS Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude